Free Trial
NASDAQ:PAVM

PAVmed Q1 2025 Earnings Report

PAVmed logo
$0.79 -0.03 (-3.65%)
Closing price 05/2/2025 03:59 PM Eastern
Extended Trading
$0.79 0.00 (-0.14%)
As of 05/2/2025 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PAVmed EPS Results

Actual EPS
N/A
Consensus EPS
-$0.40
Beat/Miss
N/A
One Year Ago EPS
N/A

PAVmed Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.02 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

PAVmed Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

PAVmed Earnings Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
See More PAVmed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PAVmed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PAVmed and other key companies, straight to your email.

About PAVmed

PAVmed (NASDAQ:PAVM) focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

View PAVmed Profile

More Earnings Resources from MarketBeat